Thymosin beta4 is cytoprotective in human gingival fibroblasts.
Thymosin beta4 (Tbeta(4)) is a naturally occurring, ubiquitous, non-toxic protein with documented wound-healing, anti-inflammatory, anti-apoptotic, and tissue-repair properties in skin, the ocular surface, and the heart. The ability of Tbeta(4) to demonstrate similar protective properties in cells of the oral cavity was analyzed using an in vitro model of cultured human gingival fibroblasts. Thymosin beta 4 significantly suppressed the secretion of interleukin-8 (IL-8) following stimulation with tumor necrosis factoralpha (TNF-alpha), suggesting that it may suppress the inflammatory response initiated by pro-inflammatory cytokines. By contrast, Tbeta(4) was not effective in protecting fibroblasts from challenge with lipopolysaccharide purified from Porphyromonas gingivalis or Escherichia coli. Thymosin beta 4 was able to protect gingival fibroblasts against the known cytotoxic effects of chlorhexidine digluconate, a mouthrinse containing chlorhexidine digluconate, and carbamide peroxide. Additionally, Tbeta(4) was able to protect gingival fibroblasts from the apoptosis that is induced by stimulation with TNF-alpha or by exposure to chlorhexidine. Because of its multifunctional roles in protecting cells against damage, Tbeta(4) may have significant potential for use as an oral heathcare aid with combined antimicrobial, anti-inflammatory, anti-apoptotic, and cytoprotective properties.
Reti
Robert
R
Department of Biomedical Sciences, University of Detroit Mercy School of Dentistry, Detroit, MI, USA.
Kwon
Edwin
E
Qiu
Pin
P
Wheater
Michelle
M
Sosne
Gabriel
G
D000891:Anti-Infective Agents, Local / Q000037:antagonists & inhibitors; D017209:Apoptosis / Q000187:drug effects; D000077463:Carbamide Peroxide; D002478:Cells, Cultured; D002710:Chlorhexidine / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D019610:Cytoprotection; D004338:Drug Combinations; D005347:Fibroblasts / Q000187:drug effects / Q000276:immunology; D005881:Gingiva / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D016209:Interleukin-8 / Q000037:antagonists & inhibitors*; D008070:Lipopolysaccharides / Q000494:pharmacology; D009067:Mouthwashes; D016877:Oxidants / Q000037:antagonists & inhibitors; D010545:Peroxides / Q000037:antagonists & inhibitors; D013947:Thymosin / Q000494:pharmacology*; D018675:Toxicity Tests; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014508:Urea / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D000099201:Thymosin beta(4)
D000891:Anti-Infective Agents, Local; D000077463:Carbamide Peroxide; D002710:Chlorhexidine; D004338:Drug Combinations; D016209:Interleukin-8; D008070:Lipopolysaccharides; D009067:Mouthwashes; D016877:Oxidants; D010545:Peroxides; D013947:Thymosin; D014409:Tumor Necrosis Factor-alpha; D014508:Urea; D000099201:Thymosin beta(4); C010882:chlorhexidine gluconate